ALK and lung cancer: Similar to BRAF and MEK inhibitors, crizotinib, which is used to treat NSCLC carrying activated anaplastic lymphoma kinase (ALK) and ROS proto-oncogene 1, receptor tyrosine kinase (ROS1), favored the ICD, likely because it triggered the pyroptosis of lung cancer cells in which GSDME is expressed ubiquitously [112].